- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03787498
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Northside Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 27287
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins
-
-
New York
-
New York, New York, United States, 10065
- NewYork-Presbyterian / Weill Cornell Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Sciences University
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Confirmed diagnosis of one of the following myeloid malignancies, based on the 2016 revision of the World Health Organization classification:
A. Relapsed or refractory AML.
I. Subjects must have received no more than 3 prior induction therapies and have no standard therapeutic option that is expected to result in a clinical benefit.
B. Relapsed or refractory MDS.
I. Subjects must have high-risk disease (intermediate or greater disease according to the revised International Prognostic Scoring System [IPSS-R]).
II. Subjects must have received no more than 3 prior therapies, 1 of which must have included a hypomethylating agent such as azacytidine or decitabine.
III. Subjects must have no standard therapeutic option that is expected to result in a clinical benefit.
- Age ≥18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
- Life expectancy of ≥3 months in the judgment of the investigator.
Adequate renal, hepatic, and coagulation parameters:
A. Measured or calculated (Cockcroft-Gault formula) creatinine clearance (CrCl) ≥60 mL/min.
B. Total bilirubin ≤1.5 × ULN unless due to Gilbert's syndrome.
C. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
D. Prothrombin time or international normalized ratio ≤1.5 × ULN.
E. Activated partial thromboplastin time ≤1.5 × ULN.
- Women of child-bearing potential must have a negative pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test to 90 days after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraception in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
- Fertile men must agree to use an effective method of birth control during the study and for 90 days after the last dose of study drug.
- Resolution (to ≤Grade 1 or baseline) of all significant toxicity associated with prior cancer therapy prior to study drug initiation. (Grade 2 alopecia or residual Grade 2 peripheral neuropathy is allowed.)
- Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements.
Exclusion Criteria:
- Prior treatment with a bromodomain inhibitor.
Any one of the following therapies:
A. Stem cell transplantation within 90 days of study drug initiation;
B. Active immunosuppressive therapy for graft-versus-host disease (GVHD);
C. GVHD prophylaxis within 2 weeks of study drug initiation.
- Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2.
- Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia.
- Active symptomatic central nervous system involvement of AML. (Individuals who have had leptomeningeal disease that was effectively treated are eligible.)
- A diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia in blast crisis.
- Known or suspected allergy to the study drug or any agent given in association with this trial.
- Women who are either pregnant or breast feeding.
- Clinically significant cardiac disease.
- Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption.
- Individuals who are known to be infected with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) or are known carriers of HBV or HCV. Individuals who are positive for HCV antibody must be negative for HCV RNA by polymerase chain reaction (PCR) to be eligible. Individuals with occult or prior HBV infection (defined as being seropositive for total hepatitis B core antibody and seronegative for hepatitis B surface antigen) may be included if HBV DNA is undetectable. These individuals must be willing to undergo additional testing per local standard of care.
Active second malignancy with the exception of any of the following:
- Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer;
- Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years;
- Low-risk prostate cancer with Gleason score <7 and prostate-specific antigen <10 ng/mL;
- Any other cancer from which the patient has been disease-free for ≥3 years.
- Major surgery or significant injury within the 14-day period prior to study drug initiation.
- Anti-cancer therapy in the period immediately preceding study drug initiation.
- Any other medical, psychological, familial, sociologic, or geographic condition that, in the judgement of the investigator, would potentially hamper compliance with the study protocol or interfere with the study endpoints or the subject's ability to participate in the study.
- Participation in any other therapeutic clinical study. (Participation in observational or registry trials is allowed.)
- Individuals who are on active anticoagulation therapy (e.g., warfarin, factor Xa inhibitors, thrombin inhibitors, heparin).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PLX2853
Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853.
Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.
|
Tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: First dose of study drug through at least 30 days after end of treatment
|
First dose of study drug through at least 30 days after end of treatment
|
|
Area under the concentration-time curve (AUC) of PLX2853
Time Frame: From first dose of PLX2853 up to 30 days after end of treatment
|
From first dose of PLX2853 up to 30 days after end of treatment
|
|
Maximum observed concentration (Cmax) of PLX2853
Time Frame: From first dose of PLX2853 up to 30 days after end of treatment
|
From first dose of PLX2853 up to 30 days after end of treatment
|
|
Time to peak concentration (Tmax) of PLX2853
Time Frame: From first dose of PLX2853 up to 30 days after end of treatment
|
From first dose of PLX2853 up to 30 days after end of treatment
|
|
Half life (t1/2) of PLX2853
Time Frame: From first dose of PLX2853 up to 30 days after end of treatment
|
From first dose of PLX2853 up to 30 days after end of treatment
|
|
Terminal elimination rate constant (Kel)
Time Frame: From first dose of PLX2853 up to 30 days after end of treatment
|
From first dose of PLX2853 up to 30 days after end of treatment
|
|
Number of participants who experience dose limiting toxicity as defined in the protocol
Time Frame: up to 18 months
|
Dose escalation will be guided by a modified continuous reassessment method (mCRM) using a Bayesian logistic regression model that follows the escalation with overdose control (EWOC) principle.
In this method, a decision to escalate to the next dose level is based on a review of all subjects who have completed the DLT observation period.
|
up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall complete remission (OCR) rate
Time Frame: From the first dose of study drug until the date of documented best response to treatment, assessed up to 18 months
|
AML - Complete Remission (CR) + CR with incomplete hematological recovery (CRi); MDS - CR
|
From the first dose of study drug until the date of documented best response to treatment, assessed up to 18 months
|
Overall response rate (ORR)
Time Frame: From the first dose of study drug until the date of documented response to treatment, assessed up to 18 months
|
AML - Complete Remission (CR) + CR with incomplete hematologic recovery (CRi) + Partial Remission (PR); MDS - CR + PR
|
From the first dose of study drug until the date of documented response to treatment, assessed up to 18 months
|
Duration of response (DOR)
Time Frame: DOR defined as the time from the initial objective response to disease progression or death, whichever occurs first, assessed up to 18 months
|
DOR defined as the time from the initial objective response to disease progression or death, whichever occurs first, assessed up to 18 months
|
|
Event-free survival (EFS)
Time Frame: EFS time is defined as the time from the first dose of PLX2853 to treatment failure, relapse after initial response or death from any cause, assessed up to 18 months.
|
EFS time is defined as the time from the first dose of PLX2853 to treatment failure, relapse after initial response or death from any cause, assessed up to 18 months.
|
|
Progression-free survival (PFS)
Time Frame: PFS time is defined as the time from the first dose of PLX2853 to disease progression or death, whichever occurs first, assessed up to 18 months.
|
PFS time is defined as the time from the first dose of PLX2853 to disease progression or death, whichever occurs first, assessed up to 18 months.
|
|
Overall survival (OS)
Time Frame: From the first dose of study drug until the date of death from any cause, assessed up to 18 months.
|
From the first dose of study drug until the date of death from any cause, assessed up to 18 months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLX124-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-risk Myelodysplastic Syndrome (MDS)
-
Assistance Publique - Hôpitaux de ParisUnknownInfection | Risk Factors | Myelodysplastic Syndrome (MDS) | IPSS High RiskFrance
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsActive, not recruitingAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Spain, Singapore, Australia, Germany, Italy, Finland, United States
-
University of UlmTerminatedAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Germany
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
GWT-TUD GmbHAmsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des MyelodysplasiesCompletedAcute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic SyndromeGermany, Netherlands, France
-
Ascentage Pharma Group Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1United States
-
Celgene CorporationCompletedLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)United States
-
Novartis PharmaceuticalsCompletedAML and High Risk MDSGermany, Italy, France, Netherlands, United States, Australia, Japan
Clinical Trials on PLX2853
-
Opna-IO LLCCompletedFollicular Lymphoma | Small Cell Lung Cancer | Solid Tumor | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Ovarian Clear Cell Carcinoma | Uveal Melanoma | Advanced MalignanciesUnited States
-
Opna-IO LLCTerminatedEpithelial Ovarian Cancer | Gynecologic NeoplasmsUnited States, Canada
-
Alliance for Clinical Trials in OncologyWithdrawnMetastatic Uveal Melanoma | Advanced Uveal Melanoma | Unresectable Uveal Melanoma
-
Opna-IO LLCTerminatedMetastatic Castration-resistant Prostate CancerUnited States, United Kingdom